- Amgen and Celgene’s Otezla Deal: Key Highlights Market Realist
- Why Amgen Thinks Celgene’s Psoriasis Drug Otezla Is Worth $13.4 Billion Bloomberg Markets and Finance
- Bristol-Meyers Deal for Celgene Moves Ahead After Sale of Psoriasis Drug Otezla Barron’s
- Bristol-Myers Moves Closer to Buying Celgene The Wall Street Journal
- Amgen to buy Celgene psoriasis drug Otezla for $13.4 billion Reuters
- View full coverage on Google News
